---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-050700"
form_type: "8-K"
ticker: "SHPH"
cik: "0001757499"
company_name: "Shuttle Pharmaceuticals Holdings, Inc."
filed_at: "2024-12-19T23:59:59+00:00"
generated_at: "2026-05-29T01:43:51.017725+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Shuttle Pharma enters $291K sponsored research agreement with UCSF for PSMA-B theranostic development

## Summary
- Sponsored research agreement with UCSF, $291,607 cost, 1-year term, for preclinical PSMA-B ligand development.
- UCSF will develop radiosynthetic methods for [18F]FPA-ACUPA probe and test binding in prostate cancer cell lines and mouse models.
- Shuttle holds exclusive license to PSMA-B IP and has filed a patent application with USPTO.
- PSMA-B ligand is a theranostic candidate for prostate cancer diagnosis and therapy, with market opportunities cited.
- Pluvicto market predicted at $2B; PSMA PET imaging market expected to reach $2.0B by 2030.

## SEC filing metadata
- accession: 0001493152-24-050700
- form_type: 8-K
- ticker: SHPH
- cik: 0001757499
- company_name: Shuttle Pharmaceuticals Holdings, Inc.
- filed_at: 2024-12-19T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1757499/000149315224050700/0001493152-24-050700-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1757499/000149315224050700/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-050700
- JSON: https://secwatch.observer/filing/0001493152-24-050700.json
- Plain text: https://secwatch.observer/filing/0001493152-24-050700.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.